Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. / Denmeade, Samuel R; Mhaka, Annastasiah M; Rosen, D Marc; Brennen, W Nathaniel; Dalrymple, Susan; Dach, Ingrid; Olesen, Claus; Gurel, Bora; DeMarzo, Angelo M; Wilding, George; Carducci, Michael A; Dionne, Craig A; Møller, Jesper Vuust; Nissen, Poul; Christensen, Søren Brøgger; Isaacs, John T.
In: Science Translational Medicine, Vol. 4, No. 140, 27.06.2012, p. 140ra86.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy
AU - Denmeade, Samuel R
AU - Mhaka, Annastasiah M
AU - Rosen, D Marc
AU - Brennen, W Nathaniel
AU - Dalrymple, Susan
AU - Dach, Ingrid
AU - Olesen, Claus
AU - Gurel, Bora
AU - DeMarzo, Angelo M
AU - Wilding, George
AU - Carducci, Michael A
AU - Dionne, Craig A
AU - Møller, Jesper Vuust
AU - Nissen, Poul
AU - Christensen, Søren Brøgger
AU - Isaacs, John T
PY - 2012/6/27
Y1 - 2012/6/27
N2 - Heterogeneous expression of drug target proteins within tumor sites is a major mechanism of resistance to anticancer therapies. We describe a strategy to selectively inhibit, within tumor sites, the function of a critical intracellular protein, the sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump, whose proper function is required by all cell types for viability. To achieve targeted inhibition, we took advantage of the unique expression of the carboxypeptidase prostate-specific membrane antigen (PSMA) by tumor endothelial cells within the microenvironment of solid tumors. We generated a prodrug, G202, consisting of a PSMA-specific peptide coupled to an analog of the potent SERCA pump inhibitor thapsigargin. G202 produced substantial tumor regression against a panel of human cancer xenografts in vivo at doses that were minimally toxic to the host. On the basis of these data, a phase 1 dose-escalation clinical trial has been initiated with G202 in patients with advanced cancer.
AB - Heterogeneous expression of drug target proteins within tumor sites is a major mechanism of resistance to anticancer therapies. We describe a strategy to selectively inhibit, within tumor sites, the function of a critical intracellular protein, the sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump, whose proper function is required by all cell types for viability. To achieve targeted inhibition, we took advantage of the unique expression of the carboxypeptidase prostate-specific membrane antigen (PSMA) by tumor endothelial cells within the microenvironment of solid tumors. We generated a prodrug, G202, consisting of a PSMA-specific peptide coupled to an analog of the potent SERCA pump inhibitor thapsigargin. G202 produced substantial tumor regression against a panel of human cancer xenografts in vivo at doses that were minimally toxic to the host. On the basis of these data, a phase 1 dose-escalation clinical trial has been initiated with G202 in patients with advanced cancer.
U2 - 10.1126/scitranslmed.3003886
DO - 10.1126/scitranslmed.3003886
M3 - Journal article
C2 - 22745436
VL - 4
SP - 140ra86
JO - Science Translational Medicine
JF - Science Translational Medicine
SN - 1946-6234
IS - 140
ER -
ID: 38405956